|
| 36702472 | COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS). | J Natl Cancer Inst | 2023 |
| 37531248 | The New NCI Precision Medicine Trials. | Clin Cancer Res | 2023 |
| 37043210 | Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial. | JAMA Surg | 2023 |
| 36975602 | Response to Song. | J Natl Cancer Inst | 2023 |
| 37133584 | Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. | N Engl J Med | 2023 |
| 37433103 | Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. | J Clin Oncol | 2023 |
| 37471685 | Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease. | J Clin Oncol | 2023 |
| 36856617 | Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. | N Engl J Med | 2023 |
| 34716198 | A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). | Clin Cancer Res | 2022 |
| 35728019 | Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. | JCO Oncol Pract | 2022 |
| 35417251 | Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. | J Clin Oncol | 2022 |
| 35902504 | ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. | Ann Surg Oncol | 2022 |
| 35900648 | Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. | Ann Surg Oncol | 2022 |
| 36228963 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. | Ann Oncol | 2022 |
| 36050448 | Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study. | Br J Cancer | 2022 |
| 34764195 | Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. | Cancer Discov | 2022 |
| 34625860 | Correction to: Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a subâ¿¿analysis of the ALTTO trial (BIG 2â¿¿06; NCCTG (Alliance) N063D). | Breast Cancer Res Treat | 2022 |
| 32951084 | Tolerability and toxicity of trastuzumab or trastuzumabâ¿¿+â¿¿lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). | Breast Cancer Res Treat | 2021 |
| 33507815 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. | J Clin Oncol | 2021 |
| 34390999 | Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. | Breast | 2021 |
| 34324367 | Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2021 |
| 34010053 | A Case-Based Approach to Understanding Complex Genetic Information in an Evolving Landscape. | Am Soc Clin Oncol Educ Book | 2021 |
| 34312396 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. | NPJ Breast Cancer | 2021 |
| 34003702 | Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. | J Clin Oncol | 2021 |
| 34081848 | Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer. | N Engl J Med | 2021 |
| 33401235 | Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. | J Natl Compr Canc Netw | 2021 |
| 33272980 | A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. | Clin Cancer Res | 2021 |
| 32725204 | Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. | JAMA Dermatol | 2020 |
| 32031889 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. | J Clin Oncol | 2020 |
| 33154022 | Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. | ESMO Open | 2020 |
| 30616442 | Sex Hormones in Women With Elevated Breast Cancer Risk Undergoing Weight Loss. | West J Nurs Res | 2019 |
| 32337479 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. | JNCI Cancer Spectr | 2019 |
| 32337478 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. | JNCI Cancer Spectr | 2019 |
| 29878225 | Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. | J Natl Cancer Inst | 2019 |
| 31240310 | Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial. | Ann Oncol | 2019 |
| 31429864 | Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape. | JAMA Oncol | 2019 |
| 31095436 | Oncologists' Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce. | J Oncol Pract | 2019 |
| 30737173 | Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. | Clin Breast Cancer | 2019 |
| 30973611 | Current Landscape of Immunotherapy in Breast Cancer: A Review. | JAMA Oncol | 2019 |
| 31134488 | Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. | Breast Cancer Res Treat | 2019 |
| 30335191 | Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. | Cancer | 2019 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 30212295 | National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. | J Clin Oncol | 2018 |
| 28335697 | Investigation of a Lifestyle Intervention in Women at High Risk of Breast Cancer. | West J Nurs Res | 2018 |
| 29254937 | Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients. | Cancer Epidemiol Biomarkers Prev | 2018 |
| 28686476 | Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer. | J Adolesc Young Adult Oncol | 2017 |
| 28649655 | Gene expression in breast and adipose tissue after 12 months of weight loss and vitamin D supplementation in postmenopausal women. | NPJ Breast Cancer | 2017 |
| 28914599 | Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment. | Radiology | 2017 |
| 28852601 | Solitary Orbital Metastasis 35 Years after a Diagnosis of Lobular Carcinoma in Situ. | Cureus | 2017 |
| 26758879 | Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety. | Cancer Prev Res (Phila) | 2016 |